Skip to main content

Table 1 Summary of clinical efficacy scores from trials evaluating abatacept

From: Abatacept in the treatment of rheumatoid arthritis

       ACR20 (%) ACR50 (%) ACR70 (%) DAS28 LDAS (%) DAS28 remission (%)
Trial authors Study phase Study cohort n Duration Background therapy A P A P A P A P A P
Moreland et al. [19] II DMARD failure 214 3 months None 53% 31%         
Kremer et al. [20] II MTX failure 339 6 months MTX 60% 35.3% 36.5% 11.8% 16.5% 1.7%     
Kremer et al. [21] II MTX failure 339 1 year MTX 62.6% 36.1% 41.7% 20.2% 20.9% 7.6% 49.6% 21.9% 34.8% 10.1%
Kremer et al. [22] III (AIM) MTX failure 652 1 year MTX 73.1% 39.7% 48.3% 18.2% 28.8% 6.1% 42.5% 9.9% 23.8% 1.9%
Genovese et al. [29] III (ATTAIN) TNF-α antagonist Failure 391 6 months MTX, other DMARD 50.4% 19.5% 20.3% 3.8% 10.2% 1.5% 17.1% 3.1% 10% 0.8%
Schiff et al. [28] III (ATTEST) MTX failure: abatacept (A) or infliximab (I) active arms 431 6 months MTX A: 66.7% 41.8% A: 40.4% 20% A: 20.5% 9.1% A: 20.7% 10.8% A: 11.3% 2.9%
       I: 59.4%   I: 37%   I: 24.2%   I: 25.6%   I: 12.8%  
     1 year MTX A: 72.4%   A: 45.5%   A: 26.3%   A: 35.3%   A: 18.7%  
       I: 55.8%   I: 36.4%   I: 20.6%   I: 22.4%   I: 12.2%  
  1. For abatacept (A), only responses for 10 mg/kg are included. ACR20/50/70, at least 20%/50%/70% improvement in the American College of Rheumatology criteria for rheumatoid arthritis; AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; ATTEST, Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA; DAS28, Disease Activity Score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; LDAS, low disease activity scores; LTE, long-term extension; MTX, methotrexate; P, placebo; TNF, tumor necrosis factor.
\